Roche’s IMpower 132 hits on progression-free survival, but Merck remains in control — for now — on frontline lung cancer
Roche just leaped forward in the rankings of the big league lung cancer game. But they’re still not ready yet to challenge a dominant Merck.
The pharma giant reported this morning that its IMpower 132 trial — a combination of its PD-L1 Tecentriq and chemo — scored promising progressive-free survival data among patients with frontline cases of non-squamous non-small cell lung cancer.
The trial, though, has not yet hit success in overall survival, leaving Merck’s dominant combination of Keytruda and chemo clearly out front. Researchers will continue to follow the more than 500 patients in the study, in bad need of a significant readout for OS.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.